A retrospective, descriptive analysis of a single-center experience with patients with metaplastic breast cancer.
← Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma →